Spyre Therapeutics, Inc.
SYRE
$44.07
$4.1810.48%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -459.15% | 69.54% | 17.99% | 20.47% | 18.44% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 163.43% | -3,859.50% | -118.52% | -47.62% | -71.63% |
| Change in Net Operating Assets | -138.13% | 165.70% | -1,491.73% | -105.26% | 4.32% |
| Cash from Operations | -20.10% | 20.29% | -13.58% | -10.20% | -26.44% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -100.00% | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -1,061.72% | -65.28% | 118,129.51% | 99.96% | -499.03% |
| Cash from Investing | -1,089.72% | -68.36% | 129,604.92% | 99.96% | -499.03% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 63,623.22% | -32.83% | 118.21% | -99.85% | 1,627.55% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 98.66% | -- | 100.00% | 35.98% | -320.51% |
| Cash from Financing | 6,837.28% | -735.16% | 484.80% | -99.94% | 1,665.27% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -193.75% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 224.23% | -150.54% | 181.03% | -329.39% | -31.68% |